The US Food and Drug Administration (FDA) has rejected Alkermes' filing for ALKS 5461 in major depressive disorder (MDD), asking for more clinical data.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.